-
AZ vaccine to be made available for everyone over 40 years of age. Fear understandable with media reporting on extremely rare blood clots but not mentioning lives saved from vaccine. Risk of harm from Covid infection causing clots is far greater.
Medical Mythbusting Commentary for April 19, 2021 Source:Ontario to expand use of AstraZeneca vaccine to people 40 and older on TuesdayUnderstanding the blood clot issue behind the AstraZeneca vaccine and its safety Reference:News – Communicating the potential benefits and harms of the Astra-Zeneca COVID-19 vaccine
tagged:
-
Sunday House Call, #786, April 18, 2021: Something in the Air: Lancet commentary outlines the evidence supporting airborne transmission of SARS-CoV-2. @DFisman #Coronavirus #Pandemic #COVID #SARSCoV2 #Airborne
The Lancet published a commentary about the evidence supporting airborne transmission of SARS-CoV-2. There are important implications for health policy decisions. Your calls about: A woman waits for her husband to return home after contracting Covid. Is a four-month delay between covid vaccine doses reasonable for someone on immunosuppressant drugs? What is the efficacy of…
tagged:
-
Pfizer CEO states that a booster of present vaccine “likely” needed with six to 12 months after second dose. And just as we have yearly flu vaccine boosters, we may have similar protocols for Covid vaccine to deal with the variants.
Medical Mythbusting Commentary for April 16, 2021 Source:Pfizer CEO says third Covid vaccine dose likely needed within 12 months
tagged:
-
Ottawa’s Associate Medical Office of Health reports that the COVID situation in the city is dire. Health care system at “significant risk” of breaking down as hospital admissions are doubling every 12 days.
Medical Mythbusting Commentary for April 15, 2021 Source:Ottawa’s COVID situation ‘the worst that it’s been to date’
tagged:
-
The war between Gut and Head. Latest news about rare blood clots associated with J & J vaccine illustrates how we calculate, process and respond to risk. Gut wants to win but taking a step back and pondering the big picture can help provide perspective.
Medical Mythbusting Commentary for April 14, 2021 Source:U.S. recommends ‘pause’ for J&J COVID-19 shot over clot reports The risk-reward calculus of the Johnson & Johnson vaccine, visualized
tagged:
-
Alberta may be overselling its best-before date for easing of Covid restrictions. Does the math/evidence support the prediction that “back to normal” will return mid-September?
Medical Mythbusting Commentary for April 13, 2021 Source:Alberta predicting no more masks or COVID-19 isolation by mid-September
tagged:
-
Observational study suggests that 1 in 3 COVID-19 may have long-term psychiatric and neurological consequences six months after infection
Medical Mythbusting Commentary for April 12, 2021 Source:1 In 3 COVID-19 Survivors Have Neurological Or Psychiatric Problems Within 6 Months Reference:6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records
tagged:
-
Have cancer? Immunosuppressed? “You can have your second dose in four months.” Preliminary study reports cancer patients’ immune response is less protective after first dose vs. healthy people. Dosing delay needs to be reviewed for vulnerable groups.
Sunday House Call, #785, April 11, 2021 Topics today include:Cancer patients could be at risk if second doses delayed beyond three weeks, experts say Reference:Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines Your calls about:…
tagged:
-
Will Covid vaccine mixing be adopted as health policy? They use different delivery systems carrying the genetic instruction set to produce the same spike protein, ergo ongoing studies are evaluating clinical outcomes to determine if assumption is true.
Medical Mythbusting Commentary for April 9, 2021 Source:Vaccine mixing ‘possible’ in Canada as countries revamp AstraZeneca plans: Njoo
tagged: